- Home
- NPV vs MCRB Comparison
NPV vs MCRB Comparison
Compare NPV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- MCRB
- Stock Information
- Founded
- NPV 1993
- MCRB 2010
- Country
- NPV United States
- MCRB United States
- Employees
- NPV N/A
- MCRB N/A
- Industry
- NPV Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- NPV Finance
- MCRB Health Care
- Exchange
- NPV Nasdaq
- MCRB Nasdaq
- Market Cap
- NPV 199.1M
- MCRB 165.3M
- IPO Year
- NPV N/A
- MCRB 2015
- Fundamental
- Price
- NPV $11.54
- MCRB $18.07
- Analyst Decision
- NPV
- MCRB Hold
- Analyst Count
- NPV 0
- MCRB 4
- Target Price
- NPV N/A
- MCRB $73.67
- AVG Volume (30 Days)
- NPV 38.9K
- MCRB 247.1K
- Earning Date
- NPV 01-01-0001
- MCRB 11-12-2025
- Dividend Yield
- NPV 3.90%
- MCRB N/A
- EPS Growth
- NPV N/A
- MCRB N/A
- EPS
- NPV N/A
- MCRB 10.22
- Revenue
- NPV N/A
- MCRB N/A
- Revenue This Year
- NPV N/A
- MCRB N/A
- Revenue Next Year
- NPV N/A
- MCRB N/A
- P/E Ratio
- NPV N/A
- MCRB $1.71
- Revenue Growth
- NPV N/A
- MCRB N/A
- 52 Week Low
- NPV $8.92
- MCRB $6.53
- 52 Week High
- NPV $11.55
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- NPV 64.07
- MCRB 52.67
- Support Level
- NPV $11.25
- MCRB $14.22
- Resistance Level
- NPV $11.62
- MCRB $24.67
- Average True Range (ATR)
- NPV 0.08
- MCRB 2.07
- MACD
- NPV 0.01
- MCRB -0.38
- Stochastic Oscillator
- NPV 65.91
- MCRB 36.81
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.